Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.

[1]  M. Rocco,et al.  Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  S. N. Davis,et al.  Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  B. Isaac.  Efficacy of Cryopreserved Recombinant Alteplase for Declotting Thrombosed Central Catheters , 2000, The Annals of pharmacotherapy.

[4]  W. Hörl,et al.  Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  J. Gould,et al.  The timing and sequence of multiple device‐related complications in patients with long term indwelling Groshong catheters , 1996, Cancer.

[6]  W. Haire,et al.  Are clinical signs accurate indicators of the cause of central venous catheter occlusion? , 1995, JPEN. Journal of parenteral and enteral nutrition.

[7]  J. Atkinson,et al.  Urokinase versus Recombinant Tissue Plasminogen Activator in Thrombosed Central Venous Catheters: , 1994, Thrombosis and Haemostasis.

[8]  P. Fauchald,et al.  Use of tissue plasminogen activator for reopening of clotted dialysis catheters. , 1993, Nephron.

[9]  A. Hannah,et al.  Thrombolysis of blocked hemodialysis catheter using recombinant tissue-type plasminogen activator. , 1991, Nephron.

[10]  J. Edney,et al.  Obstructed central venous catheters: Restoring function with a 12‐hour infusion of low‐dose urokinase , 1990, Cancer.

[11]  J. Atkinson,et al.  Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. , 1990, JPEN. Journal of parenteral and enteral nutrition.

[12]  P. Benotti,et al.  Complications and management of implanted venous access catheters. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. McCredie,et al.  Restoring patency of occluded central venous catheters. , 1980, Archives of surgery.